Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention


  Free Subscription

Articles published in Circulation

Retrieve available abstracts of 15 articles:
HTML format

Single Articles

    August 2022
  1. RIDKER PM, Rifai N, MacFadyen J, Glynn RJ, et al
    Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1beta, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholi
    Circulation. 2022;146:372-379.
    PubMed     Abstract available

    May 2022
  2. BERGMARK BA, Marston NA, Bramson CR, Curto M, et al
    Effect of Vupanorsen on Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70.
    Circulation. 2022;145:1377-1386.
    PubMed     Abstract available

    February 2022
  3. SEMOVA I, Levenson AE, Krawczyk J, Bullock K, et al
    Insulin Prevents Hypercholesterolemia by Suppressing 12a-Hydroxylated Bile Acid Production.
    Circulation. 2022 Feb 23. doi: 10.1161/CIRCULATIONAHA.120.045373.
    PubMed     Abstract available

    June 2021
    Evinacumab Approval Adds a New Option for Homozygous Familial Hypercholesterolemia With a Hefty Price Tag.
    Circulation. 2021;143:2494-2496.

  5. ROHATGI A, Westerterp M, von Eckardstein A, Remaley A, et al
    HDL in the 21st Century: A Multifunctional Roadmap for Future HDL Research.
    Circulation. 2021;143:2293-2309.
    PubMed     Abstract available

    April 2021
  6. POWELL-WILEY TM, Poirier P, Burke LE, Despres JP, et al
    Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association.
    Circulation. 2021 Apr 22:CIR0000000000000973. doi: 10.1161/CIR.0000000000000973.
    PubMed     Abstract available

    November 2020
    Familial Hypercholesterolemia: A Reportable Disorder.
    Circulation. 2020;142:1999-2001.

    October 2020
  8. MSZAR R, Nasir K, Santos RD
    Coronary Artery Calcification in Familial Hypercholesterolemia: An Opportunity for Risk Assessment and Shared Decision Making With the Power of Zero?
    Circulation. 2020;142:1405-1407.

    June 2020
  9. KHERA AV, Hegele RA
    What Is Familial Hypercholesterolemia, and Why Does It Matter?
    Circulation. 2020;141:1760-1763.

  10. HOVINGH GK, Lepor NE, Kallend D, Stoekenbroek RM, et al
    Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia: The ORION-2 Pilot Study.
    Circulation. 2020;141:1829-1831.

    May 2020
  11. HU P, Dharmayat KI, Stevens CAT, Sharabiani MTA, et al
    Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis.
    Circulation. 2020 May 29. doi: 10.1161/CIRCULATIONAHA.119.044795.

  12. LOUPY A, Coutance G, Bonnet G, Van Keer J, et al
    Identification and characterization of Trajectories of Cardiac Allograft Vasculopathy After Heart Transplantation: A Population Based Study.
    Circulation. 2020 May 4. doi: 10.1161/CIRCULATIONAHA.119.044924.
    PubMed     Abstract available

    April 2020
  13. STONE NJ, Blumenthal RS, Lloyd-Jones D, Grundy SM, et al
    Comparing Primary Prevention Recommendations: A Focused Look at United States and European Guidelines on Dyslipidemia.
    Circulation. 2020;141:1117-1120.

  14. VIRANI SS, Smith SC Jr, Stone NJ, Grundy SM, et al
    Secondary Prevention for Atherosclerotic Cardiovascular Disease: Comparing Recent US and European Guidelines on Dyslipidemia.
    Circulation. 2020;141:1121-1123.

    November 2019
  15. DAMASK A, Steg PG, Schwartz GG, Szarek M, et al
    Patients with High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit from Alirocumab Treatment in the Odyssey Outcomes Trial.
    Circulation. 2019 Nov 11. doi: 10.1161/CIRCULATIONAHA.119.044434.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Dyslipidemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.